Literature DB >> 2439808

Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics.

H U Janka, A G Ziegler, G Disselhoff, H Mehnert.   

Abstract

In a double-blind crossover study, the influence of bisoprolol and placebo was tested in 20 noninsulin-dependent diabetics with concomitant essential hypertension. A 2-week washout placebo period was followed by two treatment periods of 2 weeks each with 10 mg bisoprolol or placebo. Compared with placebo, bisoprolol did not change blood glucose, haemoglobin A1 (HbA1), and glucosuria. No hypoglycaemia was observed. Serum cholesterol and triglyceride levels remained constant. Systolic (SBP) and diastolic (DBP) blood pressure, and heart rate (HR) were significantly (p less than 0.01) reduced after 2 weeks of bisoprolol therapy, compared with placebo. It was concluded that bisoprolol, in a dose therapeutically effective in essential hypertension, has no influence on carbohydrate and lipid metabolism in noninsulin-dependent patients with diabetes mellitus; and 10 mg bisoprolol is effective for the normalisation of SBP and DBP in mildly hypertensive diabetics. Since bisoprolol was well tolerated in the dosage studied, it can be recommended for noninsulin-dependent diabetics with hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439808     DOI: 10.1097/00005344-198511001-00018

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).

Authors:  S O'Byrne; J Feely
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 2.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 4.  Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?

Authors:  Michal Vrablik; Alberto Corsini; Eva Tůmová
Journal:  Curr Atheroscler Rep       Date:  2022-02-16       Impact factor: 5.113

5.  Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis.

Authors:  Jennifer A Hirst; Andrew J Farmer; Benjamin G Feakins; Jeffrey K Aronson; Richard J Stevens
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

Authors:  V Channaraya; R K Marya; M Somasundaram; Debashish Mitra; K D Tibrewala
Journal:  BMJ Open       Date:  2012-05-14       Impact factor: 2.692

Review 7.  Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Authors:  Waleed AlHabeeb; Sanaa Mrabeti; Ahmed Adel Ibrahim Abdelsalam
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-09       Impact factor: 3.947

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.